Chimeric Betaretrovirus Envelope Protein for Targeted Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy platforms face challenges such as non-specific delivery, immunogenicity, and the need for multiple proteins to achieve cell-specific binding and entry, leading to inefficiencies in transgene delivery and expression.
Innovation Solution
The development of betaretroviruses and recombinant betaretroviral envelope (rENV) proteins that can be engineered to target specific cell surface receptors, allowing for site-specific transgene delivery and expression through the use of engineered delivery vehicles and virus-like particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current gene therapy platforms use multiple proteins for cell-specific binding and entry, then cell targeting capability is improved, but device complexity increases and transgene delivery efficiency decreases
Solution Approach 1:
The patent combines multiple separate proteins (attachment protein and cell entry protein) into a single chimeric protein. The attachment domain binds to specific cell surface receptors while the cell entry domain facilitates membrane fusion, allowing one protein to perform functions previously requiring multiple separate proteins. This reduces device complexity while maintaining cell targeting capability.
Solution Approach 2:
The chimeric protein is designed to perform multiple functions simultaneously: it provides both attachment to target cells via its attachment domain and membrane fusion via its cell entry domain. This multi-functional design eliminates the need for separate proteins, reducing complexity while improving delivery efficiency through coordinated action of both functions within a single protein structure.
2Adaptability or versatility
If current gene therapy platforms use multiple proteins for receptor binding and membrane fusion, then cell-specific entry is achieved, but productivity of transgene delivery decreases
Solution Approach 1:
By merging the attachment and cell entry functions into a single chimeric protein, the patent ensures that both functions occur in a coordinated manner at the same location and time. This eliminates delays and inefficiencies associated with sequential action of separate proteins, thereby improving transgene delivery productivity while maintaining cell-specific entry capability.
Solution Approach 2:
The chimeric protein is pre-configured with both attachment and cell entry domains in a single molecular structure, allowing the attachment domain to bind to the target cell receptor and immediately trigger the cell entry domain to facilitate membrane fusion. This preliminary configuration of both functions in one protein eliminates the need for separate sequential steps, improving delivery efficiency.
3Quantity of substance
If adenovirus vectors are used for gene therapy, then transgene delivery capacity is improved, but immunogenicity increases and safety decreases
Solution Approach 1:
The patent uses a lentiviral vector as an intermediary delivery system rather than adenovirus. The lentiviral vector is engineered to express the chimeric protein on its surface, allowing it to mediate target cell entry through the chimeric protein's attachment and cell entry domains. This intermediary approach avoids the strong immunogenicity of adenovirus while maintaining transgene delivery capacity.
Solution Approach 2:
The patent copies the successful attachment and cell entry mechanism from the chimeric protein design and applies it to a lentiviral vector platform. By expressing the chimeric protein on the lentiviral surface, the system replicates the targeted entry capability without adopting the harmful immunogenic properties of adenovirus, thereby improving safety while maintaining delivery capacity.
4Object-affected harmful factors
If AAV vectors are used for gene therapy, then safety profile is improved, but transgene capacity is limited to approximately 5 kb
Solution Approach 1:
The patent uses a lentiviral vector system that can accommodate larger transgene capacities compared to AAV. The lentiviral platform is segmented to allow for expression of the chimeric protein along with larger therapeutic transgenes, overcoming the 5 kb capacity limitation of AAV while maintaining an improved safety profile through the use of self-inactivating vector designs and the absence of strong pre-existing immunity.
Data Source
AI summary
The disclosure relates to betaretroviruses (genus Betaretrovirus), and recombinant betaretroviral envelope (rENV) protein for use in viral vector platforms, an engineered delivery vehicle and gene therapy, their associated methods of use and manufacture. In particular, the present disclosure provides compositions and methods to tune betavirus envelope proteins such that they target a particular cell surface receptor; i.e., are cell and/or tissue-type specific, allowing for better site-specific transgene delivery and expression.